CY1105027T1 - Αναστολεις της βιοσυνθεσης της συνθασης του ενδοϋπεροξειδιου η της προσταγλανδινης - Google Patents
Αναστολεις της βιοσυνθεσης της συνθασης του ενδοϋπεροξειδιου η της προσταγλανδινηςInfo
- Publication number
- CY1105027T1 CY1105027T1 CY20061100599T CY061100599T CY1105027T1 CY 1105027 T1 CY1105027 T1 CY 1105027T1 CY 20061100599 T CY20061100599 T CY 20061100599T CY 061100599 T CY061100599 T CY 061100599T CY 1105027 T1 CY1105027 T1 CY 1105027T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cox
- inhibitors
- cyclooxygenase
- endoperoxide
- compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 150000003180 prostaglandins Chemical class 0.000 title 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 4
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract 4
- 108010037464 Cyclooxygenase 1 Proteins 0.000 abstract 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 abstract 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 abstract 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 abstract 2
- 102000001708 Protein Isoforms Human genes 0.000 abstract 2
- 108010029485 Protein Isoforms Proteins 0.000 abstract 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 2
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/18—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91866197A | 1997-08-22 | 1997-08-22 | |
| PCT/US1998/017618 WO1999010332A1 (en) | 1997-08-22 | 1998-08-20 | Prostaglandin endoperoxide h synthase biosynthesis inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1105027T1 true CY1105027T1 (el) | 2010-03-03 |
Family
ID=25440748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061100599T CY1105027T1 (el) | 1997-08-22 | 2006-05-09 | Αναστολεις της βιοσυνθεσης της συνθασης του ενδοϋπεροξειδιου η της προσταγλανδινης |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1005460B1 (enExample) |
| JP (1) | JP2002511887A (enExample) |
| AT (1) | ATE319691T1 (enExample) |
| CA (1) | CA2294548A1 (enExample) |
| CY (1) | CY1105027T1 (enExample) |
| DE (1) | DE69833774T2 (enExample) |
| DK (1) | DK1005460T3 (enExample) |
| ES (1) | ES2260846T3 (enExample) |
| PT (1) | PT1005460E (enExample) |
| WO (1) | WO1999010332A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6307047B1 (en) | 1997-08-22 | 2001-10-23 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
| RU2209813C2 (ru) | 1997-11-19 | 2003-08-10 | Кова Ко., Лтд. | Производные пиридазина, лекарственные средства на их основе и способ лечения артрита |
| TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
| DK1124804T3 (da) * | 1998-10-27 | 2005-12-12 | Abbott Lab | Inhibitorer for biosyntesen af prostaglandin-endoperoxid-H-syntase |
| JP2000247959A (ja) | 1999-02-26 | 2000-09-12 | Kowa Co | ピリダジン−３−オン誘導体及びこれを含有する医薬 |
| DE60016191T2 (de) | 1999-12-08 | 2005-12-22 | Pharmacia Corp., Chicago | Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt |
| CN100486573C (zh) | 1999-12-23 | 2009-05-13 | 硝化医药股份有限公司 | 硝基化的和亚硝基化的环加氧酶-2抑制剂、组合物及其用途 |
| US6664256B1 (en) | 2000-07-10 | 2003-12-16 | Kowa Co., Ltd. | Phenylpyridazine compounds and medicines containing the same |
| AR038957A1 (es) | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
| US7211598B2 (en) | 2002-06-28 | 2007-05-01 | Nitromed, Inc. | Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| AU2004221966A1 (en) | 2003-03-18 | 2004-09-30 | Kowa Co., Ltd. | Water-soluble phenylpyridazine derivative and medicine containing the same |
| WO2004098619A2 (en) | 2003-05-07 | 2004-11-18 | Osteologix A/S | Treating cartilage / bone conditions with water-soluble strontium salts |
| JPWO2005012259A1 (ja) * | 2003-07-30 | 2007-09-27 | 興和株式会社 | オステオポンチン産生抑制方法 |
| DE102004010207A1 (de) | 2004-03-02 | 2005-09-15 | Aventis Pharma S.A. | Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate |
| PH12012502411A1 (en) | 2005-05-10 | 2019-07-17 | Intermune Inc | Method of modulating stress-activated protein kinase system |
| DE102005057924A1 (de) * | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102006037478A1 (de) * | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
| DE102007025718A1 (de) * | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | Pyridazinonderivate |
| US8304413B2 (en) | 2008-06-03 | 2012-11-06 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| RU2692485C2 (ru) | 2014-04-02 | 2019-06-25 | Интермьюн, Инк. | Противофиброзные пиридиноны |
| KR102557900B1 (ko) | 2016-09-07 | 2023-07-19 | 트러스티즈 오브 터프츠 칼리지 | 면역-dash 억제제와 pge2 길항제를 이용한 병행 요법 |
| CA3209491A1 (en) | 2021-03-15 | 2022-09-22 | Saul Yedgar | Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3934436A1 (de) * | 1989-06-01 | 1991-04-18 | Thomae Gmbh Dr K | 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
-
1998
- 1998-08-20 DK DK98944529T patent/DK1005460T3/da active
- 1998-08-20 ES ES98944529T patent/ES2260846T3/es not_active Expired - Lifetime
- 1998-08-20 DE DE69833774T patent/DE69833774T2/de not_active Expired - Fee Related
- 1998-08-20 WO PCT/US1998/017618 patent/WO1999010332A1/en not_active Ceased
- 1998-08-20 EP EP98944529A patent/EP1005460B1/en not_active Expired - Lifetime
- 1998-08-20 PT PT98944529T patent/PT1005460E/pt unknown
- 1998-08-20 CA CA002294548A patent/CA2294548A1/en not_active Abandoned
- 1998-08-20 AT AT98944529T patent/ATE319691T1/de not_active IP Right Cessation
- 1998-08-20 JP JP51459699A patent/JP2002511887A/ja not_active Ceased
-
2006
- 2006-05-09 CY CY20061100599T patent/CY1105027T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999010332A1 (en) | 1999-03-04 |
| CA2294548A1 (en) | 1999-03-04 |
| ES2260846T3 (es) | 2006-11-01 |
| ATE319691T1 (de) | 2006-03-15 |
| DE69833774D1 (en) | 2006-05-04 |
| JP2002511887A (ja) | 2002-04-16 |
| DE69833774T2 (de) | 2007-04-26 |
| EP1005460A1 (en) | 2000-06-07 |
| EP1005460B1 (en) | 2006-03-08 |
| PT1005460E (pt) | 2006-07-31 |
| DK1005460T3 (da) | 2006-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1105027T1 (el) | Αναστολεις της βιοσυνθεσης της συνθασης του ενδοϋπεροξειδιου η της προσταγλανδινης | |
| ATE302759T1 (de) | Prostaglandin endoperoxyde h synthase biosynthese inhibitoren | |
| CA2299300A1 (en) | Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors | |
| Esser et al. | Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2 | |
| CY1108297T1 (el) | Μεσα ανταγωνιστικης επιλεκτικης συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης | |
| NO20001359D0 (no) | Synergistisk analgetisk kombinasjon av opioid analgetikum og cyklooksigenase-2 inhibitor | |
| EA199900837A1 (ru) | Способ применения ингибиторов циклооксигеназы-2 для предупреждения сердечно-сосудистых расстройств | |
| TR200102958T2 (tr) | Siklooksijenaz-2 inhibitörleri olarak 4,5-diaril-3(2H)-furanon türevleri. | |
| EA199900853A1 (ru) | Замещенные производные бензопирана для лечения воспалительных процессов | |
| DE69942459D1 (de) | Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung | |
| EA200000251A1 (ru) | Производные резорцинола | |
| DE69906311D1 (de) | Diarylbenzopyranderivate als cyclooxygenase-2-inhibitoren | |
| WO2002010393A3 (en) | Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof | |
| Klein et al. | Generation of 8‐epi‐prostaglandin F2α in isolated rat kidney glomeruli by a radical‐independent mechanism | |
| TR200000478T2 (tr) | Prostaglandin endoperoksit H sentaz biyosentezi inhibitörleri olarak arilpiridazinonlar. | |
| ATE244232T1 (de) | (methylsulfonyl)phenyl-2-(5h)-furanone mit sauerstoff-bindung als cox-2-hemmer | |
| DE60206044D1 (de) | Speissschutzmuffe | |
| BR0317864A (pt) | Bateria | |
| ATE366260T1 (de) | Kalzium-aktivierte kaliumkanäle mit niedriger und mittlerer leitfähigkeit und ihre verwendungen. | |
| DE69931814D1 (de) | Umwandlung von cox-inhibierenden, nicht cox-2 selektiven inhibitoren in derivate von cox-2 selektiven inhibitoren | |
| CY1106814T1 (el) | Εκλεκτικη διαδικασια οξειδωσης με ενισχυμενη ασφαλεια | |
| CO5280149A1 (es) | Ciclooxigenasa-1(cox-1) canina y ciclooxigenasa-2(cox-2) | |
| Berg et al. | Pharmacology of a selective cyclooxygenase-2 inhibitor, HN-56249: a novel compound exhibiting a marked preference for the human enzyme in intact cells | |
| BG100697A (en) | Fluoropropylthiazoline derivative and herbicide | |
| DE69905621D1 (de) | 3-(thio-substituierte amido)-lactame, verwendbar als inhibitoren der matrix-metalloproteinase |